Richard Newcomb Stillwell - 13 May 2025 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Director
Signature
/s/ Jessica Morris as attorney-in-fact
Issuer symbol
TNXP
Transactions as of
13 May 2025
Net transactions value
$0
Form type
4
Filing time
15 May 2025, 16:51:59 UTC
Previous filing
24 May 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stillwell Richard Newcomb Director C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN ST., SUITE 101, CHATHAM /s/ Jessica Morris as attorney-in-fact 15 May 2025 0001966861

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +10,000 $0.000000 10,000 13 May 2025 Common Stock 10,000 $20.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders.